Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CER To Play A Larger Role In Investment Decisions – Merck's McElwee

Executive Summary

Pharmaceutical companies are going to need to consider the impact of the growing emphasis on comparative effectiveness earlier in the drug development and investment decision process, Merck & Co.'s Newell McElwee said.
Advertisement

Related Content

Stimulus-Funded CER: Few Awards Are For Drug Vs. Drug Studies
Stimulus-Funded CER: Few Awards Are For Drug Vs. Drug Studies
Pfizer's Lewis-Hall To Represent Pharma Interests On PCORI Board
CMS/FDA Parallel Review: Agencies Weighing Process For Planning Trials That Satisfy Both
CMS/FDA Parallel Review: Agencies Weighing Process For Planning Trials That Satisfy Both
WellPoint's CER Guide Describes How It Will Determine Usefulness Of Studies
WellPoint CE Study Results In Coverage Adjustment For Oral Asthma Drugs

Topics

Advertisement
UsernamePublicRestriction

Register

PS052623

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel